CELLDEX THERAPEUTICS INC NEW's ticker is CLDX and the CUSIP is 15117B202. A total of 147 filers reported holding CELLDEX THERAPEUTICS INC NEW in Q3 2023. The put-call ratio across all filers is 0.86 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $3,366,824 | -18.9% | 122,341 | -0.0% | 2.26% | -19.8% |
| Q2 2023 | $4,151,098 | -5.0% | 122,343 | +0.7% | 2.81% | -12.7% |
| Q1 2023 | $4,371,570 | -14.7% | 121,500 | +5.7% | 3.22% | +2.1% |
| Q4 2022 | $5,125,550 | -31.8% | 115,000 | -57.0% | 3.15% | -2.5% |
| Q3 2022 | $7,511,000 | +4.3% | 267,195 | 0.0% | 3.23% | -19.4% |
| Q2 2022 | $7,204,000 | -34.5% | 267,195 | -17.3% | 4.01% | -21.9% |
| Q1 2022 | $10,998,000 | -16.3% | 322,898 | -5.1% | 5.14% | -7.0% |
| Q4 2021 | $13,141,000 | -27.9% | 340,098 | +0.8% | 5.52% | -14.1% |
| Q3 2021 | $18,222,000 | -63.4% | 337,500 | -77.3% | 6.43% | -67.7% |
| Q2 2021 | $49,739,000 | +137.3% | 1,487,406 | +46.2% | 19.88% | +163.0% |
| Q1 2021 | $20,961,000 | -26.5% | 1,017,524 | -37.5% | 7.56% | -2.6% |
| Q4 2020 | $28,514,000 | +24.5% | 1,627,500 | +5.3% | 7.76% | +24.7% |
| Q3 2020 | $22,912,000 | +76.2% | 1,545,000 | +54.5% | 6.22% | +65.7% |
| Q2 2020 | $13,000,000 | – | 1,000,000 | – | 3.76% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ACUTA CAPITAL PARTNERS, LLC | 1,017,524 | $20,961,000 | 7.56% |
| Octagon Capital Advisors LP | 561,398 | $11,565,000 | 4.36% |
| COMMODORE CAPITAL LP | 369,951 | $7,621,000 | 3.04% |
| Opaleye Management Inc. | 985,000 | $20,291,000 | 2.98% |
| VR Adviser, LLC | 1,240,610 | $25,557,000 | 2.77% |
| TSP Capital Management Group, LLC | 359,229 | $7,400,000 | 2.61% |
| RTW INVESTMENTS, LP | 3,908,947 | $80,524,000 | 1.26% |
| Ghost Tree Capital, LLC | 250,000 | $5,150,000 | 1.21% |
| Tri Locum Partners LP | 196,672 | $4,051,000 | 1.00% |
| Redmile Group, LLC | 3,387,788 | $69,788,000 | 0.98% |